Low-dose total skin electron beam therapy as a debulking agent for cutaneous T-cell lymphoma: An open-label prospective phase II study

British Journal of Dermatology

Volumn 166, Issue 2, 2012, Pages 399-404

  Kamstrup, M R ^a   Lindahl, L M ^b   Gniadecki, R ^a   Iversen, L ^b   Skov, L ^a   Petersen, P M ^a   Loft, A ^a   Specht, L ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BEXAROTENE; ETRETIN; METHOTREXATE; PREDNISOLONE;

ADULT; AGED; ALOPECIA; ANHIDROSIS; ANKLE EDEMA; ARTICLE; BLISTER; CANCER GROWTH; CANCER RELAPSE; CANCER STAGING; CLINICAL ARTICLE; DRY SKIN; ERYTHEMA; EYE IRRITATION; FEMALE; FOOT ULCER; HUMAN; HYPERPIGMENTATION; MALE; MYCOSIS FUNGOIDES; NAIL DISEASE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; PUVA; RADIATION DOSE; RADIATION INJURY; TOTAL SKIN ELECTRON THERAPY; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, RADIATION; ELECTRONS; FEMALE; HUMANS; MALE; MIDDLE AGED; MYCOSIS FUNGOIDES; PROSPECTIVE STUDIES; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 84856210258     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2011.10670.x     Document Type: Article

References (27)

1. Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification for cutaneous lymphomas. Blood 2005; 105: 3768-85.
2. Agar NS, Wedgeworth E, Crichton S, et al. Survival outcomes and prognostic factors in mycosis fungoides/Sézary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal. J Clin Oncol 2010; 28: 4730-9.
3. Trautinger F, Knobler R, Willemze R, et al. EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome. Eur J Cancer 2006; 42: 1014-30.
4. Jones GW, Hoppe RT, Glatstein E,. Electron beam treatment for cutaneous T-cell lymphoma. Hematol Oncol Clin North Am 1995; 9: 1057-76.
5. Introcaso CE, Micaily B, Richardson SK, et al. Total skin electron beam therapy may be associated with improvement of peripheral blood disease in Sézary syndrome. J Am Acad Dermatol 2008; 58: 592-5.
6. Hoppe RT,. Total skin electron beam therapy in the management of mycosis fungoides. Front Radiat Ther Oncol 1991; 25: 80-9.
7. Becker M, Hoppe RT, Knox SJ,. Multiple courses of high-dose total skin electron beam therapy in the management of mycosis fungoides. Int J Radiat Oncol Biol Phys 1995; 32: 1445-9.
8. Wilson LD, Quiros PA, Kolenik SA, et al. Additional courses of total skin electron beam therapy in the treatment of patients with recurrent cutaneous T-cell lymphoma. J Am Acad Dermatol 1996; 35: 69-73.
9. Harrison C, Young J, Navi D, et al. Revisiting low-dose total skin electron beam therapy in mycosis fungoides. Int J Radiat Oncol Biol Phys 2011; 81: e651-7.
10. Kamstrup MR, Specht L, Skovgaard GL, et al. A prospective, open-label study of low-dose total skin electron beam therapy in mycosis fungoides. Int J Radiat Oncol Biol Phys 2008; 71: 1204-7.
11. Olsen E, Vonderheid E, Pimpinelli, et al. Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 2007; 110: 1713-22.
12. Cox RS, Heck RJ, Fessenden P, et al. Development of total-skin electron therapy at two energies. Int J Radiat Oncol Biol Phys 1990; 18: 659-69.
13. Lindahl LM, Kamstrup MR, Petersen PM, et al. Total skin electron beam therapy for cutaneous T-cell lymphoma: a nationwide cohort study from Denmark. Acta Oncol 2011; 50: 1199-205.
14. Simon R,. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989; 10: 1-10.
15. Chinn DM, Chow S, Kim YH, et al. Total skin electron beam therapy with or without adjuvant topical nitrogen mustard or nitrogen mustard alone as initial treatment of T2 and T3 mycosis fungoides. Int J Radiat Oncol Biol Phys 1999; 43: 951-8.
16. Navi D, Riaz N, Levin YS, et al. The Stanford University experience with conventional-dose, total skin electron-beam therapy in the treatment of generalized patch or plaque (t2) and tumor (t3) mycosis fungoides. Arch Dermatol 2011; 147: 561-7.
17. Hoppe RT, Fuks Z, Bagshaw MA,. Radiation therapy in the management of cutaneous T-cell lymphomas. Cancer Treat Rep 1979; 63: 625-32.
18. Demierre MF, Gan S, Jones J, et al. Significant impact of cutaneous T-cell lymphoma on patients' quality of life: results of a 2005 National Cutaneous Lymphoma Foundation Survey. Cancer 2006; 107: 2504-11.
19. Ganem G, Lambin P, Socie G, et al. Potential role for low dose limited-field radiation therapy (2 Ã 2 grays) in advanced low-grade non-Hodgkin's lymphomas. Hematol Oncol 1994; 12: 1-8.
20. Jacobs P, King HS,. A randomized prospective comparison of chemotherapy to total body irradiation as initial treatment for the indolent lymphoproliferative diseases. Blood 1987; 69: 1642-6.
21. Johannsson J, Specht L, Mejer J, et al. Phase II study of palliative low-dose local radiotherapy in disseminated indolent non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Int J Radiat Oncol Biol Phys 2002; 54: 1466-70.
22. Lybeert ML, Meerwaldt JH, Deneve W,. Long-term results of low dose total body irradiation for advanced non-Hodgkin lymphoma. Int J Radiat Oncol Biol Phys 1987; 13: 1167-72.
23. Sawyer EJ, Timothy AR,. Low dose palliative radiotherapy in low grade non-Hodgkin's lymphoma. Radiother Oncol 1997; 42: 49-51.
24. Neelis KJ, Schimmel EC, Vermeer MH, et al. Low-dose palliative radiotherapy for cutaneous B- and T-cell lymphomas. Int J Radiat Oncol Biol Phys 2009; 74: 154-8.
25. Jones GW, Kacinski BM, Wilson LD, et al. Total skin electron radiation in the management of mycosis fungoides: consensus of the European Organization for Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Project Group. J Am Acad Dermatol 2002; 47: 364-70.
26. Kuo PH, Carlson KR, Christensen I, et al. FDG-PET/CT for the evaluation of response to therapy of cutaneous T-cell lymphoma to vorinostat (suberoylanilide hydroxamic acid, SAHA) in a phase II trial. Mol Imaging Biol 2008; 10: 306-14.
27. Tsai EY, Taur A, Espinosa L, et al. Staging accuracy in mycosis fungoides and Sézary syndrome using integrated positron emission tomography and computed tomography. Arch Dermatol 2006; 142: 577-84.